Tudor Investment Corp Et Al Makes New $169,000 Investment in Metacrine, Inc. (NASDAQ:MTCR)
Tudor Investment Corp Et Al Makes New $169,000 Investment in Metacrine, Inc. (NASDAQ:MTCR)
In related news, major shareholder Braden Michael Leonard purchased 101,384 shares of the company's stock in a transaction that occurred on Monday, December 19th. The shares were purchased at an average price of $0.40 per share, for a total transaction of $40,553.60. Following the transaction, the insider now directly owns 5,990,349 shares of the company's stock, valued at approximately $2,396,139.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through Tudor Investment Corp Et Al bought a new stake in Metacrine, Inc. (NASDAQ:MTCR – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 349,100 shares of the company's stock, valued at approximately $169,000. Tudor Investment Corp Et Al owned about 0.82% of Metacrine as of its most recent filing with the Securities and Exchange Commission.
根據最近向美國證券交易委員會提交的 13F 表格，帝舵表投資公司等人在第三季度收購了 Metacrine，Inc.（NASDAQ：MTCR — 獲得評級）的新股份。該基金買入了公司股票 349,100 股，價值約 16 萬美元。在最近向證券交易委員會提交文件時，帝舵表投資公司等人擁有約 0.82％ 的 Metacrine。
Several other institutional investors and hedge funds have also made changes to their positions in MTCR. Bank of New York Mellon Corp purchased a new stake in shares of Metacrine in the 1st quarter valued at about $126,000. Renaissance Technologies LLC lifted its holdings in shares of Metacrine by 84.5% in the 1st quarter. Renaissance Technologies LLC now owns 423,100 shares of the company's stock valued at $258,000 after purchasing an additional 193,800 shares during the last quarter. State Street Corp lifted its holdings in shares of Metacrine by 482.8% in the 2nd quarter. State Street Corp now owns 72,186 shares of the company's stock valued at $36,000 after purchasing an additional 59,800 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Metacrine by 10.5% in the 1st quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after purchasing an additional 24,964 shares during the last quarter. 34.28% of the stock is owned by hedge funds and other institutional investors.
其他一些機構投資者和對沖基金也對其在 MTCR 的頭寸進行了更改。紐約梅隆銀行在第一季度購買了價值約 126,000 美元的 Metacrine 股份的新股份。文藝復興科技有限責任公司在第一季度將其對梅特克林股份的持有量提高了 84.5％。文藝復興科技有限責任公司現在擁有該公司股票的 423,100 股價值為 258,000 美元，在上個季度額外購買 193,800 股股票後。國街公司在第二季度將其對梅特克林股份的持有量提高了 482.8％。州街公司現在擁有該公司的 72,186 股股份，價值 36,000 美元，在上一季度額外購買 59,800 股股票後。最後，美國銀行 DE 在第一季度將其對梅特克林股份的持有量提高了 10.5％。美國銀行在上一季度額外購買 24,964 股股票後，現在擁有該公司 263,340 股，價值 161,000 美元的股票。34.28％ 的股票由對沖基金和其他機構投資者擁有。
Metacrine Stock Performance
甲基林股票表現
Shares of MTCR stock opened at $0.54 on Friday. The stock has a market capitalization of $22.99 million, a PE ratio of -0.52 and a beta of -0.76. Metacrine, Inc. has a 52-week low of $0.30 and a 52-week high of $0.68. The stock's 50-day moving average price is $0.50 and its 200 day moving average price is $0.46. The company has a quick ratio of 12.15, a current ratio of 12.15 and a debt-to-equity ratio of 0.34.
MTCR 股票上週五以 0.54 美元開盤。該股的市值為 22.99 萬美元，私募股票比率為 -0.52，貝塔值為 -0.76。梅塔克林的 52 周低點為 0.30 美元，52 周高點為 0.68 美元。該股票的 50 天移動平均價為 0.50 美元，其 200 日移動平均價為 0.46 美元。該公司的快速比率為 12.15，流動比率為 12.15，債務與權益比率為 0.34。
Insider Activity at Metacrine
梅塔克林的內幕活動
In related news, major shareholder Braden Michael Leonard purchased 101,384 shares of the company's stock in a transaction that occurred on Monday, December 19th. The shares were purchased at an average price of $0.40 per share, for a total transaction of $40,553.60. Following the transaction, the insider now directly owns 5,990,349 shares of the company's stock, valued at approximately $2,396,139.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Metacrine news, CEO Preston Klassen sold 380,605 shares of the business's stock in a transaction that occurred on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total transaction of $156,048.05. Following the transaction, the chief executive officer now owns 541,905 shares in the company, valued at approximately $222,181.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Braden Michael Leonard bought 101,384 shares of the company's stock in a transaction on Monday, December 19th. The shares were acquired at an average price of $0.40 per share, for a total transaction of $40,553.60. Following the transaction, the insider now directly owns 5,990,349 shares in the company, valued at approximately $2,396,139.60. The disclosure for this purchase can be found here. 13.80% of the stock is currently owned by insiders.
在相關新聞中，主要股東布拉登邁克爾·倫納德在 12 月 19 日星期一發生的交易中購買了該公司股票的 101,384 股。這些股份以每股 0.40 美元的平均價格購買，總交易額為 40,553.60 美元。交易完成後，內幕人士現直接擁有該公司股票的 5,990,349 股，價值約為 2,396,139.60 美元。該交易在向證券交易委員會提交的文件中披露，該文件可通過以下方式訪問 此超連結。在其他 Metacrine 新聞中，首席執行官普雷斯頓·克拉森（普雷斯頓 Klassen）在 1 月 26 日（星期四）發生的交易中出售了該業務股票的 380,605 股。該股票以 0.41 美元的平均價格出售，總交易額為 156,048.05 美元。交易完成後，首席執行官現擁有該公司 541,905 股股份，價值約為 222,181.05 元。該交易在與證券交易委員會的法律文件中披露，該文件可通過以下方式訪問 證券交易所網站。此外，主要股東布拉登邁克爾·倫納德在 12 月 19 日（星期一）的一項交易中購買了該公司股票的 101,384 股。這些股份以每股 0.40 美元的平均價格購入，總交易額為 40,553.60 美元。交易完成後，內幕人士現在直接擁有該公司的 5,990,349 股股份，價值約為 2,396,139.60 美元。可以找到此次購買的披露 這裡。13.80％ 的股票目前由內部人士擁有。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a research report on Wednesday, November 16th.
此外，HC 溫賴特在 11 月 16 日（星期三）的一份研究報告中重申了對米特琳股票的「中性」評級。
About Metacrine
關於梅塔克林
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
- 獲取有關二甲基林（MTCR）的研究報告的免費副本
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
- 甲骨文已經說話:股價下跌 5%
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
